Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 27, 2021Today, NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced the election of The Honorable Herbert Raymond "H.R." McMaster (LTG US Army, Ret.) as a member of the company's Board of Directors,...
-
May 26, 2021- NRx Pharmaceuticals (Nasdaq:NRXP) to collaborate with Ministries of Health of Georgia, Hungary, and Ukraine to conduct phase III development of ZYESAM™ in coordination with the Senator Richard Lugar Research Institute
Today, NRx Pharmaceuticals, Inc., (Nasdaq:NRXP) (NRx) through its Georgia subsidiary, announced that it has signed a master services agreement with Cromos Pharma, LLC, headquartered in Longview,...
-
May 25, 2021- Newly formed publicly traded company NRx Pharmaceuticals, Inc. (NRx) to be traded under the ticker symbol "NRXP" on the Nasdaq Global Market
Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition...
-
May 18, 2021- After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 600 Patients
NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3 Critical Care...
-
April 28, 2021
NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its...
Click here to view our corporate presentation or on the image below
 |
